AR091939A1 - 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos - Google Patents
4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenosInfo
- Publication number
- AR091939A1 AR091939A1 ARP130102708A ARP130102708A AR091939A1 AR 091939 A1 AR091939 A1 AR 091939A1 AR P130102708 A ARP130102708 A AR P130102708A AR P130102708 A ARP130102708 A AR P130102708A AR 091939 A1 AR091939 A1 AR 091939A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- group
- heterocyclyl
- halogen
- Prior art date
Links
- 125000005843 halogen group Chemical group 0.000 abstract 10
- 229910052736 halogen Inorganic materials 0.000 abstract 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 8
- 125000000623 heterocyclic group Chemical group 0.000 abstract 8
- 125000001072 heteroaryl group Chemical group 0.000 abstract 6
- 125000001424 substituent group Chemical group 0.000 abstract 6
- 150000002367 halogens Chemical class 0.000 abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 3
- 125000001153 fluoro group Chemical group F* 0.000 abstract 3
- 125000004076 pyridyl group Chemical group 0.000 abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 125000004452 carbocyclyl group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicación 1: Compuestos caracterizados porque tienen la fórmula (1) en donde A se selecciona del grupo Aᵃ que consiste enlos restos del grupo de fórmulas (2) en donde los grupos fenilo, piridinilo, pirimidinilo, piridazinilo y pirazinilo mencionados con anterioridad están sustituidos por R¹ y R²; R¹ se selecciona del grupo R¹ᵃ que consiste en H, halógeno, NC-, alquilo C₁₋₆-, alquilo C₁₋₆-O-, cicloalquilo C₃₋₆ y R⁸-(CH₂)ₙ-O- con n = 0, 1, 2, 3 ó 4, en donde los grupos alquilo C₁₋₆-, alquilo C₁₋₆-O-, cicloalquilo C₃₋₆ y R⁸-(CH₂)ₙ-O- mencionados con anterioridad pueden estar sustituidos en forma opcional por 1 a 5 sustituyentes seleccionados en forma independiente del grupo que consiste en halógeno, HO- y en forma opcional por 1 a 7 átomos de flúor sustituidos por alquilo C₁₋₃-; R² se selecciona del grupo R²ᵃ que consiste en H, HO-, halógeno, alquilo C₁₋₆-, alquilo C₁₋₆-O-, cicloalquilo C₃₋₆, heterociclilo, heterociclil-alquilo C₁₋₃-, fenilo, heteroarilo, R⁸-(CH₂)ₙ-O- con n = 0, 1, 2, 3 ó 4, y R⁸-(CH₂)ₘ-(CH)(CH₃)(CH₂)ₒ-O- con m = 0, 1 ó 2 y o = 0, 1 ó 2 en donde los grupos alquilo C₁₋₆-, alquilo C₁₋₆-O-, cicloalquilo C₃₋₆, heterociclilo, heterociclil-alquilo C₁₋₃-, fenilo, heteroarilo, R⁸-(CH₂)ₙ-O- y R⁸-(CH₂)ₘ(CH)(CH₃)-(CH₂)ₒ-O mencionados con anterioridad pueden estar sustituidos en forma opcional por 1 a 5 sustituyentes seleccionados en forma independiente del grupo que consiste en halógeno, HO-, en forma opcional por 1 a 7 átomos de flúor sustituidos por alquilo C₁₋₃-O-, y en forma opcional por 1 a 7 átomos de flúor sustituidos por alquilo C₁₋₃-; R³ se selecciona del grupo R³ᵃ que consiste en H, halógeno, NC-, alquilo C₁₋₄- y cicloalquilo C₃₋₆, en donde los grupos alquilo C₁₋₄- y cicloalquilo C₃₋₆ mencionados con anterioridad pueden estar sustituidos en forma opcional por 1 a 9 sustituyentes seleccionados en forma independiente del grupo que consiste en halógeno, NC-, HO-, alquilo C₁₋₃- y alquilo C₁₋₃-O-; R⁴, R⁵ se seleccionan en forma independiente entre sí del grupo R⁴ᵃ/R⁵ᵃ que consiste en H, halógeno, NC-, HO-, alquilo C₁₋₆-, alquilo C₁₋₆-O-, cicloalquilo C₃₋₈, cicloalquilo C₃₋₈-alquilo C₁₋₃-, cicloalquilo C₃₋₈-O-, heterociclil-O-, heterociclilo, heteroarilo, R⁷-CH₂-O- y R⁷-(CH₂)₂-O-, en donde los grupos alquilo C₁₋₆-, alquilo C₁₋₆-O-, cicloalquilo C₃₋₈, cicloalquilo C₃₋₈-alquilo C₁₋₃, cicloalquilo C₃₋₈-O-, heterociclil-O-, heterociclilo, heteroarilo, R⁷-CH₂-O- y R⁷-(CH₂)₂-O mencionados con anterioridad, pueden estar sustituidos en forma opcional por 1 a 5 sustituyentes seleccionados en forma independiente del grupo que consiste en halógeno, en forma opcional por 1 a 5 átomos de halógeno, sustituidos por alquilo C₁₋₂, y en forma opcional por 1 a 5 átomos de halógeno sustituidos por alquilo C₁₋₂-O-; R⁶ se selecciona del grupo R⁶ᵃ que consiste en H, NC-, alquilo C₁₋₆-, cicloalquilo C₃₋₈, cicloalquilo C₃₋₈-alquilo C₁₋₃- y cicloalquilo C₃₋₈-O- en donde el grupo alquilo C₁₋₆ mencionado con anterioridad puede estar sustituido en forma opcional por 1 - 3 átomos de halógeno; R⁷ se selecciona del grupo R⁷ᵃ que consiste en H, carbociclilo, heterociclilo y heteroarilo, en donde los grupos carbociclilo, heterociclilo y heteroarilo mencionados con anterioridad pueden estar sustituidos en forma opcional por 1 a 4 sustituyentes seleccionados en forma independiente del grupo que consiste en HO-, en forma opcional por 1 a 3 átomos de halógeno sustituidos por alquilo C₁₋₄-, en forma opcional por 1 a 3 átomos de halógeno sustituidos por alquilo C₁₋₄-O- y halógeno; R⁸ se selecciona del grupo R⁸ᵃ que consiste en cicloalquilo C₃₋₆, heterociclilo, heterociclil-alquilo C₁₋₃-, fenilo y piridilo, en donde los grupos cicloalquilo C₃₋₆, heterociclilo, heterociclil-alquilo C₁₋₃-, fenilo y piridilo mencionados con anterioridad pueden estar sustituidos en forma opcional por 1 a 5 sustituyentes seleccionados en forma independiente del grupo que consiste en HO-, flúor y en forma opcional por 1 a 7 átomos de halógeno sustituidos por alquilo C₁₋₃-; los tautómeros de los mismos, los estereoisómeros de los mismos, las mezclas de los mismos, los solvatos de los mismos, los hidratos de los mismos y las sales de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12178713 | 2012-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR091939A1 true AR091939A1 (es) | 2015-03-11 |
Family
ID=48906250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130102708A AR091939A1 (es) | 2012-07-31 | 2013-07-30 | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20140045856A1 (es) |
| EP (1) | EP2882749B1 (es) |
| JP (1) | JP6356671B2 (es) |
| KR (1) | KR20150037950A (es) |
| CN (1) | CN104428302B (es) |
| AP (1) | AP2015008202A0 (es) |
| AR (1) | AR091939A1 (es) |
| AU (1) | AU2013298621B2 (es) |
| BR (1) | BR112015002118A2 (es) |
| CA (1) | CA2880447A1 (es) |
| CL (1) | CL2015000096A1 (es) |
| CO (1) | CO7310531A2 (es) |
| EA (1) | EA028958B1 (es) |
| EC (1) | ECSP15006871A (es) |
| GE (1) | GEP201706707B (es) |
| IL (1) | IL236494A0 (es) |
| MA (1) | MA37798B1 (es) |
| MX (1) | MX2015000965A (es) |
| NZ (1) | NZ703797A (es) |
| PE (1) | PE20150706A1 (es) |
| PH (1) | PH12015500211B1 (es) |
| SG (1) | SG11201500772VA (es) |
| TN (1) | TN2015000022A1 (es) |
| TW (1) | TW201418255A (es) |
| UA (1) | UA115561C2 (es) |
| UY (1) | UY34955A (es) |
| WO (1) | WO2014019979A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
| JP2014526453A (ja) * | 2011-09-09 | 2014-10-06 | ハー・ルンドベック・アクチエゼルスカベット | ピリジン化合物およびそれらの使用 |
| US20140045856A1 (en) * | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
| WO2016145614A1 (en) | 2015-03-17 | 2016-09-22 | Merck Sharp & Dohme Corp. | Triazolyl pyrimidinone compounds as pde2 inhibitors |
| US10287269B2 (en) | 2015-03-26 | 2019-05-14 | Merck Sharp & Dohme Corp. | Pyrazolyl pyrimidinone compounds as PDE2 inhibitors |
| EP3291817B1 (en) | 2015-05-05 | 2019-10-02 | Merck Sharp & Dohme Corp. | Heteroaryl-pyrimidinone compounds as pde2 inhibitors |
| WO2016183741A1 (en) | 2015-05-15 | 2016-11-24 | Merck Sharp & Dohme Corp. | Pyrimidinone amide compounds as pde2 inhibitors |
| CN107614501B (zh) * | 2015-05-20 | 2020-01-14 | 广东众生睿创生物科技有限公司 | 羟基嘌呤类化合物及其应用 |
| WO2016191935A1 (en) | 2015-05-29 | 2016-12-08 | Merck Sharp & Dohme Corp. | 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
| WO2016192083A1 (en) | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
| WO2016209749A1 (en) | 2015-06-25 | 2016-12-29 | Merck Sharp & Dohme Corp. | Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors |
| WO2017000276A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic compounds as pde2 inhibitors |
| WO2017000277A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Substituted triazolo bicycliccompounds as pde2 inhibitors |
| EP3156405A1 (en) | 2015-10-13 | 2017-04-19 | Boehringer Ingelheim International GmbH | Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide |
| CN109310700A (zh) | 2016-04-04 | 2019-02-05 | 希诺皮亚生物科学公司 | 使用曲匹地尔治疗锥体外系综合征 |
| AR112457A1 (es) * | 2017-08-02 | 2019-10-30 | Lilly Co Eli | Derivados de [1,2,4]triazolo[4,3-a]pirazin-6(5h)-ona |
| CN111447930A (zh) | 2017-11-23 | 2020-07-24 | 奥斯陆大学医院公司 | 心动过速的治疗 |
| WO2021195425A1 (en) | 2020-03-26 | 2021-09-30 | Sinopia Biosciences, Inc. | Isotopically-labelled trapidil derivatives |
| CN115960101B (zh) * | 2022-12-30 | 2024-10-18 | 海南大学 | 7-氧代-4,5,6,7-四氢吡唑并吡啶酰胺类化合物及其制备方法和应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000319278A (ja) * | 1999-05-11 | 2000-11-21 | Ono Pharmaceut Co Ltd | 縮合ピラジン化合物およびその化合物を有効成分とする薬剤 |
| JP2000319277A (ja) * | 1999-05-11 | 2000-11-21 | Ono Pharmaceut Co Ltd | 縮合ピラジン化合物およびその化合物を有効成分とする薬剤 |
| DE10108752A1 (de) | 2001-02-23 | 2002-09-05 | Bayer Ag | Neue Substituierte Imidazotriazinone |
| EP1613629A1 (en) | 2003-03-27 | 2006-01-11 | Pfizer Products Inc. | Substituted 4-amino 1,2,4 triazolo 4,3-a quinoxalines |
| WO2005041957A1 (en) | 2003-10-29 | 2005-05-12 | Pfizer Products Inc. | Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors |
| CA2549510A1 (en) | 2003-12-16 | 2005-07-07 | Pfizer Products Inc. | Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors |
| EP1548011A1 (en) | 2003-12-23 | 2005-06-29 | Neuro3D | Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof |
| FR2865331A1 (fr) | 2004-01-21 | 2005-07-22 | France Telecom | Procede de connexion d'un reseau domestique a un serveur cops distant et dispositif associe |
| FR2870539B1 (fr) | 2004-05-19 | 2006-08-04 | Greenpharma Sa Sa | Nouvelles methodes et medicaments |
| BRPI0514586A (pt) | 2004-09-02 | 2008-06-17 | Altana Pharma Ag | triazolftalazinas |
| NZ555661A (en) | 2005-01-05 | 2010-11-26 | Nycomed Gmbh | Triazolophthalazines as PDE2-inhibitors |
| ES2397082T3 (es) | 2005-01-05 | 2013-03-04 | Nycomed Gmbh | Triazoloftalazinas como inhibidores de PDE2 |
| BRPI0502411A (pt) | 2005-03-31 | 2006-11-28 | Univ Minas Gerais | processo de desenvolvimento de substáncias como inibidores potentes e seletivos de isoformas de fosfodiesterases dos tipos 1 a 5 (pde1,pde2,pde3, pde4, pde5) na base de diocleìna, fluranol ou análogos e suas composições farmacêuticas para o estudo e tratamento de doenças cardiovasculares e produtos associados |
| MX2008009475A (es) | 2006-01-23 | 2008-10-20 | Amira Pharmaceuticals Inc | Inhibidores triciclicos de 5-lipoxigenasa. |
| WO2007121319A2 (en) | 2006-04-14 | 2007-10-25 | University Of California | Compostions and methods for determining and predicting treatment responses for depression and anxiety |
| TW200815436A (en) | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| TW200817400A (en) * | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| DE102006048693A1 (de) | 2006-10-14 | 2008-04-17 | Bayer Healthcare Ag | Inhibition der PDE2A |
| JP5578786B2 (ja) * | 2006-12-13 | 2014-08-27 | あすか製薬株式会社 | キノキサリン誘導体 |
| US20090143361A1 (en) * | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 |
| TWI501965B (zh) | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
| US20100120741A1 (en) | 2008-09-10 | 2010-05-13 | Kalypsys, Inc. | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| WO2010047956A1 (en) | 2008-10-08 | 2010-04-29 | Bristol-Myers Squibb Company | Azolopyrrolone melanin concentrating hormone receptor-1 antagonists |
| US20100120762A1 (en) | 2008-11-07 | 2010-05-13 | Wyeth | Triazine derivatives as inhibitors of phosphodiesterases |
| EP2406250B1 (en) * | 2009-03-11 | 2015-08-12 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| EP2266985A1 (en) * | 2009-06-26 | 2010-12-29 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Tricyclic Pyrimidine Derivatives as Wnt antagonists |
| CN107141309A (zh) | 2011-01-11 | 2017-09-08 | 桑诺维恩药品公司 | 杂芳基化合物及其使用方法 |
| US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
| US10604523B2 (en) | 2011-06-27 | 2020-03-31 | Janssen Pharmaceutica Nv | 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives |
| WO2013034758A1 (en) | 2011-09-09 | 2013-03-14 | H. Lundbeck A/S | Substituted triazolopyrazines and uses thereof |
| JP2014526453A (ja) | 2011-09-09 | 2014-10-06 | ハー・ルンドベック・アクチエゼルスカベット | ピリジン化合物およびそれらの使用 |
| AR088082A1 (es) | 2011-10-13 | 2014-05-07 | Lilly Co Eli | Moduladores selectivos del receptor androgeno |
| JP6426603B2 (ja) | 2012-06-26 | 2018-11-21 | ヤンセン ファーマシューティカ エヌ．ベー． | 神経障害または代謝障害の治療に使用するための、１−アリール−４−メチル−［１，２，４］トリアゾロ［４，３−ａ］−キノキサリン化合物などのＰＤＥ２阻害剤とＰＤＥ１０阻害剤との組合せ |
| US20140045856A1 (en) * | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
-
2013
- 2013-07-18 US US13/945,008 patent/US20140045856A1/en not_active Abandoned
- 2013-07-26 US US13/951,531 patent/US9085584B2/en active Active
- 2013-07-29 SG SG11201500772VA patent/SG11201500772VA/en unknown
- 2013-07-29 NZ NZ703797A patent/NZ703797A/en not_active IP Right Cessation
- 2013-07-29 EP EP13742632.6A patent/EP2882749B1/en active Active
- 2013-07-29 CN CN201380037349.6A patent/CN104428302B/zh not_active Expired - Fee Related
- 2013-07-29 PE PE2015000102A patent/PE20150706A1/es not_active Application Discontinuation
- 2013-07-29 CA CA2880447A patent/CA2880447A1/en not_active Abandoned
- 2013-07-29 MA MA37798A patent/MA37798B1/fr unknown
- 2013-07-29 KR KR20157002607A patent/KR20150037950A/ko not_active Withdrawn
- 2013-07-29 AU AU2013298621A patent/AU2013298621B2/en not_active Ceased
- 2013-07-29 EA EA201500182A patent/EA028958B1/ru not_active IP Right Cessation
- 2013-07-29 AP AP2015008202A patent/AP2015008202A0/xx unknown
- 2013-07-29 JP JP2015524750A patent/JP6356671B2/ja active Active
- 2013-07-29 WO PCT/EP2013/065894 patent/WO2014019979A1/en not_active Ceased
- 2013-07-29 GE GEAP201313748A patent/GEP201706707B/en unknown
- 2013-07-29 UA UAA201501673A patent/UA115561C2/uk unknown
- 2013-07-29 MX MX2015000965A patent/MX2015000965A/es unknown
- 2013-07-29 BR BR112015002118A patent/BR112015002118A2/pt not_active IP Right Cessation
- 2013-07-30 AR ARP130102708A patent/AR091939A1/es unknown
- 2013-07-30 TW TW102127314A patent/TW201418255A/zh unknown
- 2013-07-31 UY UY0001034955A patent/UY34955A/es unknown
-
2014
- 2014-12-28 IL IL236494A patent/IL236494A0/en unknown
-
2015
- 2015-01-14 CL CL2015000096A patent/CL2015000096A1/es unknown
- 2015-01-16 TN TNP2015000022A patent/TN2015000022A1/fr unknown
- 2015-01-29 CO CO15018184A patent/CO7310531A2/es unknown
- 2015-01-30 PH PH12015500211A patent/PH12015500211B1/en unknown
- 2015-02-25 EC ECIEPI20156871A patent/ECSP15006871A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR091939A1 (es) | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos | |
| AR123048A2 (es) | Moduladores de p2x7 | |
| AR090847A1 (es) | Compuestos moduladores del receptor huerfano retinoideo (ror) | |
| AR123089A2 (es) | Compuesto de piridinona | |
| AR094668A1 (es) | Amidas como moduladores de canales de sodio | |
| AR092742A1 (es) | Piridinonas antifibroticas | |
| AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| AR099363A1 (es) | Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil y pirrolo[2,3-d]piridinil acrilamidas | |
| MX384426B (es) | Proceso para preparar derivados de fenil sulfamoilpirrolamidas | |
| AR094346A1 (es) | Derivados de azaindol como inhibidores de las proteína quinasas | |
| AR089865A1 (es) | Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio | |
| AR095192A1 (es) | Quinolina y quinazolinamidas como modulares de canales de sodio | |
| AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| EA201301302A1 (ru) | Производные пиридина и пиразина | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| AR107042A1 (es) | Inhibidores de la tirosina quinasa de bruton y métodos de su uso | |
| AR118123A2 (es) | Derivados de isoxazolidina, proceso para preparar dichos compuestos, composición farmacéutica y combinación | |
| AR091519A1 (es) | Inhibidores pirrolopirazona de tanquirasa | |
| AR087328A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
| AR101359A1 (es) | Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo | |
| AR093036A1 (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
| AR093077A1 (es) | ANTAGONISTAS DE mGlu2/3 PARA EL TRATAMIENTO DE LOS TRASTORNOS AUTISTAS | |
| AR097087A1 (es) | Derivados de oxoquinazolinil-butanamida | |
| EA201390163A1 (ru) | Гетеробициклические производные в качетстве ингибиторов hcv | |
| AR098492A1 (es) | Derivados de purina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |